WO1996039442A1 - G-protein receptor htnad29 - Google Patents

G-protein receptor htnad29 Download PDF

Info

Publication number
WO1996039442A1
WO1996039442A1 PCT/US1995/007288 US9507288W WO9639442A1 WO 1996039442 A1 WO1996039442 A1 WO 1996039442A1 US 9507288 W US9507288 W US 9507288W WO 9639442 A1 WO9639442 A1 WO 9639442A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
receptor
dna
polynucleotide
protein
Prior art date
Application number
PCT/US1995/007288
Other languages
English (en)
French (fr)
Inventor
Yi Li
Rebecca A. Fuldner
Original Assignee
Human Genome Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences, Inc. filed Critical Human Genome Sciences, Inc.
Priority to EP95923763A priority Critical patent/EP0832126A4/en
Priority to PCT/US1995/007288 priority patent/WO1996039442A1/en
Priority to CNB951979256A priority patent/CN1147505C/zh
Priority to JP9500379A priority patent/JPH11506341A/ja
Priority to AU28204/95A priority patent/AU714642B2/en
Priority to KR1019970709012A priority patent/KR19990022531A/ko
Priority to CA002221706A priority patent/CA2221706A1/en
Publication of WO1996039442A1 publication Critical patent/WO1996039442A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
PCT/US1995/007288 1995-06-06 1995-06-06 G-protein receptor htnad29 WO1996039442A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP95923763A EP0832126A4 (en) 1995-06-06 1995-06-06 G-PROTEIN RECEPTOR HTNAD29
PCT/US1995/007288 WO1996039442A1 (en) 1995-06-06 1995-06-06 G-protein receptor htnad29
CNB951979256A CN1147505C (zh) 1995-06-06 1995-06-06 G蛋白受体htnad29
JP9500379A JPH11506341A (ja) 1995-06-06 1995-06-06 Ｇタンパク質レセプターｈｔｎａｄ２９
AU28204/95A AU714642B2 (en) 1995-06-06 1995-06-06 G-protein receptor HTNAD29
KR1019970709012A KR19990022531A (ko) 1995-06-06 1995-06-06 Ｇ-단백질 수용체 ｈｔｎａｄ２９
CA002221706A CA2221706A1 (en) 1995-06-06 1995-06-06 G-protein receptor htnad29

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/007288 WO1996039442A1 (en) 1995-06-06 1995-06-06 G-protein receptor htnad29

Publications (1)

Publication Number Publication Date
WO1996039442A1 true WO1996039442A1 (en) 1996-12-12

Family

ID=22249278

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/007288 WO1996039442A1 (en) 1995-06-06 1995-06-06 G-protein receptor htnad29

Country Status (7)

Country Link
EP (1) EP0832126A4 (zh)
JP (1) JPH11506341A (zh)
KR (1) KR19990022531A (zh)
CN (1) CN1147505C (zh)
AU (1) AU714642B2 (zh)
CA (1) CA2221706A1 (zh)
WO (1) WO1996039442A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860502A1 (en) * 1997-02-24 1998-08-26 Smithkline Beecham Corporation cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor
WO2003065045A2 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the gpr65 receptor
US6733990B1 (en) 1999-08-03 2004-05-11 Millennium Pharmaceuticals, Inc. Nucleic acid encoding 15571, a GPCR-like molecule of the secretin-like family
WO2004112823A1 (en) 2003-06-20 2004-12-29 Novartis Ag Proton-sensing g-protein coupled receptors and dna sequences thereof
US6919176B2 (en) 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
EP1676861A3 (en) * 1998-10-13 2006-07-19 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human G protein-coupled receptors
AU2004203102B2 (en) * 1998-10-12 2007-10-18 Arena Pharmaceuticals, Inc. Human G Protein-Coupled Receptors
WO2008101354A1 (en) * 2007-02-22 2008-08-28 Merck Frosst Canada Ltd Gpr65 as a therapeutic target in allergic airway inflammation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5462856A (en) * 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
AU655850B2 (en) * 1991-10-01 1995-01-12 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A method of identifying ligands and antagonists of ligands
AU4855393A (en) * 1992-09-10 1994-03-29 New York University Polypeptides of g-coupled receptor proteins, and compositions and methods thereof
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
FEBS LETTERS, Vol. 271, issued October 1990, EVA et al., "Molecular Cloning of a Novel G Protein-Coupled Receptor that May Belong to the Neuropeptide Receptor Family", pages 81-84. *
FEBS LETTERS, Vol. 284, No. 2, issued June 1991, MEYERHOF et al., "Molecular Cloning of a Novel Putative G-Protein Coupled Receptor Expressed During Rat Spermiogenesis", pages 155-160. *
PROC. NATL. ACAD. SCI. U.S.A., Vol. 87, issued April 1990, ROSS et al., "RTA, a Candidate G Protein-Coupled Receptor: Cloning, Sequencing and Tissue Distribution", pages 3052-3056. *
SCIENCE, Vol. 244, issued 05 May 1989, LIBERT et al., "Selective Amplification and Cloning of Four New Members of the G Protein-Coupled Receptor Family", pages 568-572. *
SCIENCE, Vol. 249, issued 27 July 1990, SCOTT et al., "Searching for Peptide Ligands with an Epitope Library", pages 386-390. *
See also references of EP0832126A4 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 265, No. 16, issued 05 June 1990, HLA et al., "An Abundant Transcript Induced in Differentiating Human Endothelial Cells Encodes a Polypeptide with Structural Similarities to G-Protein-Coupled Receptors", pages 9308-9316. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0860502A1 (en) * 1997-02-24 1998-08-26 Smithkline Beecham Corporation cDNA clone HDPBI30 that encodes a novel human 7-transmembrane receptor
US6221627B1 (en) 1997-02-24 2001-04-24 Smithkline Beecham Corporation cDNA clone HDPB130 that encodes a novel human 7-transmembrane receptor
AU2004203102B2 (en) * 1998-10-12 2007-10-18 Arena Pharmaceuticals, Inc. Human G Protein-Coupled Receptors
EP1676861A3 (en) * 1998-10-13 2006-07-19 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human G protein-coupled receptors
US6733990B1 (en) 1999-08-03 2004-05-11 Millennium Pharmaceuticals, Inc. Nucleic acid encoding 15571, a GPCR-like molecule of the secretin-like family
US6919176B2 (en) 2001-05-07 2005-07-19 Amgen Inc. Polypeptides and nucleic acids associated with cancer
WO2003065045A2 (en) * 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the gpr65 receptor
WO2003065045A3 (en) * 2002-02-01 2004-02-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the gpr65 receptor
WO2004112823A1 (en) 2003-06-20 2004-12-29 Novartis Ag Proton-sensing g-protein coupled receptors and dna sequences thereof
AU2004248913B2 (en) * 2003-06-20 2007-06-21 Novartis Ag Proton-sensing G-protein coupled receptors and DNA sequences thereof
WO2008101354A1 (en) * 2007-02-22 2008-08-28 Merck Frosst Canada Ltd Gpr65 as a therapeutic target in allergic airway inflammation

Also Published As

Publication number Publication date
AU714642B2 (en) 2000-01-06
JPH11506341A (ja) 1999-06-08
CN1193980A (zh) 1998-09-23
KR19990022531A (ko) 1999-03-25
AU2820495A (en) 1996-12-24
EP0832126A4 (en) 2000-01-12
CN1147505C (zh) 2004-04-28
CA2221706A1 (en) 1996-12-12
EP0832126A1 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
US20050196831A1 (en) Human G-protein chemokine receptor (CCR5) HDGNR10
US20110201030A1 (en) Human G-Protein Chemokine Receptor (CCR5) HDGNR10
US5776729A (en) Human G-protein receptor HGBER32
US20050214281A1 (en) G-protein coupled receptor
US20050266527A1 (en) Human G-protein receptor HIBEF51
WO1996039435A1 (en) Human g-protein receptor hpraj70
AU714642B2 (en) G-protein receptor HTNAD29
US20020106740A1 (en) Human G-protein receptor HPRAJ70
US7393650B2 (en) Method of producing an antibody to G-protein parathyroid hormone receptor HLTDG74
US20110112177A1 (en) Human G-Protein Coupled Receptor (HETGQ23)
WO1997024929A1 (en) Human g-protein coupled receptor
EP1146055A2 (en) Human G-protein chemokine receptor HDGNR10 (CCR5 receptor)
EP1149582A2 (en) Human G-protein chemokine receptor HDGNR10 (CCR5 receptor). Uses thereof
US20050059114A1 (en) G-protein receptor HTNAD29
US20080312178A1 (en) Human G-Protein Receptor HGBER32
AU760468B2 (en) G-protein receptor HTNAD29
US20060014243A1 (en) Human G-protein chemokine receptor HSATU68
EP0871668A1 (en) Human g-protein receptor hibef51
WO1996039433A1 (en) G-protein parathyroid hormone receptor hltdg74
AU2003235001A1 (en) G-Protein Receptor HTNAD29
AU3535300A (en) Human G-protein coupled receptor (HETGQ23)
AU3535200A (en) Human G-protein coupled receptor (HETGQ23)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95197925.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1997 500379

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2221706

Country of ref document: CA

Ref document number: 2221706

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019970709012

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1995923763

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995923763

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970709012

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019970709012

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1995923763

Country of ref document: EP